Tyra Biosciences, Inc. (TYRA) News
Filter TYRA News Items
TYRA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TYRA News Highlights
- For TYRA, its 30 day story count is now at 3.
- Over the past 3 days, the trend for TYRA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest TYRA News From Around the Web
Below are the latest news stories about TYRA BIOSCIENCES INC that investors may wish to consider to help them evaluate TYRA as an investment opportunity.
Tyra Biosciences to Participate in Upcoming Investor ConferencesTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate in the following investor conferences: |
What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'Tyra Biosciences, Inc. (TYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
Wall Street Analysts Believe Tyra Biosciences, Inc. (TYRA) Could Rally 59.17%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 59.2% in Tyra Biosciences, Inc. (TYRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Tyra Biosciences GAAP EPS of -$0.28 beats by $0.09
|
Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although... |
Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)Tyra Biosciences, Inc. (TYRA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and HighlightsTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter and year ended December 31, 2022, and highlighted recent corporate progress. |
Should You Buy Tyra Biosciences (TYRA) Ahead of Earnings?Tyra Biosciences (TYRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. |
Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into AchondroplasiaTyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptors (FGFR) biology, today announced that it is expanding development of TYRA-300 into achondroplasia (ACH) based on positive preclinical results demonstrated in a study performed in collaboration with the Imagine Institute in Paris, France. Achondroplasia, the most common form of dwarfism, is a sk |
Tyra Biosciences to Present at Upcoming Investor ConferencesTyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will present at the following investor conferences: |